Have Pfizer and Moderna published complete clinical trial datasets for their flu vaccines?

1. Pfizer released full phase‑3 results — what “full data” means in coverage

Journalistic coverage states Pfizer “released the full data” from its phase‑3 trial in which the mRNA flu vaccine outperformed Sanofi’s Fluzone by about 34.5% and enrolled more than 18,000 participants across multiple countries ^[2][1][3]. Reporting emphasizes the trial’s size, primary outcome (laboratory‑confirmed influenza), and that most observed cases were influenza A — information consistent across outlets ^[1][2].

2. Independent caveats reporters flagged about Pfizer’s dataset

Media reports and summaries note limits tied to strain mix and comparator choice: most cases were influenza A, so efficacy against influenza B was less clear, and the control vaccine used was a standard dose egg‑based shot rather than high‑dose or adjuvanted formulations often recommended for older adults, a point raised in analysis pieces ^[2][6]. Coverage also notes higher (but described as similar) reactogenicity compared with the control ^[2][3].

3. Moderna’s position: setbacks, delays and planned filings — not a released full dataset

Sources show Moderna experienced disappointing early results in parts of its flu program and delayed a combination flu/COVID filing after FDA requests; Moderna has said it will seek approval for a standalone flu shot later, but current reporting in these sources does not show Moderna publishing a complete phase‑3 dataset equivalent to Pfizer’s disclosed data ^[5][3][4]. Available sources do not mention a public Moderna phase‑3 dataset for a marketed flu vaccine ^[5][3].

4. What “published complete clinical trial datasets” typically entails — and what reporters actually saw

When outlets say a company “released full data,” they usually refer to complete trial results in peer‑reviewed papers, sponsor data releases, regulatory filings, or press releases with supplementary tables. Coverage here presents Pfizer’s comprehensive phase‑3 results to journalists and in press summaries ^[2][1][3]. Whether the company published individual participant‑level datasets or raw case‑level data is not specified in these stories; available sources do not mention release of de‑identified participant‑level datasets for independent reanalysis ^[2][1][3].

5. Competing perspectives and potential agendas to note

Industry and financial coverage frames Pfizer’s dataset as evidence the mRNA platform can improve flu prevention and as a positive commercial development ^[4][2]. Opposing voices and political commentators — who have been critical of mRNA vaccines since COVID — are flagged in commentary pieces that warn of reputational and political headwinds that could affect uptake or regulatory reception, though those pieces do not dispute the trial numbers reported ^[5][6]. Readers should note the trial was funded by Pfizer, a fact mentioned in reporting and relevant when assessing independence ^[3].

6. Bottom line and transparency gap

Based on the sources provided: Pfizer has publicly released detailed phase‑3 trial results and media outlets report “full data” demonstrating a 34.5% efficacy advantage in a large trial ^[2][1][3]. Moderna has had program delays and has not, in these reports, published an equivalent complete phase‑3 dataset for a marketed flu vaccine ^[5][3][4]. Available sources do not mention whether either company has deposited participant‑level raw trial datasets in public repositories for independent reanalysis; that specific level of data release is not documented in the cited reporting ^[2][1].

Limitations: this summary uses only the provided reporting and does not include regulatory filings, journal supplements, or company data portals that might contain additional files; those sources are not in the set you gave me and therefore not referenced here.